Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators. Chevalier B, et al. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010. JACC Cardiovasc Interv. 2008. PMID: 19463354 Free article. Clinical Trial.
Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators. Chevalier B, et al. Circ Cardiovasc Interv. 2009 Jun;2(3):188-95. doi: 10.1161/CIRCINTERVENTIONS.108.823443. Epub 2009 May 8. Circ Cardiovasc Interv. 2009. PMID: 20031715 Clinical Trial.
The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
Grube E, Chevalier B, Smits P, Džavík V, Patel TM, Mullasari AS, Wöhrle J, Stuteville M, Dorange C, Kaul U; SPIRIT V Investigators. Grube E, et al. Among authors: chevalier b. JACC Cardiovasc Interv. 2011 Feb;4(2):168-75. doi: 10.1016/j.jcin.2010.11.006. JACC Cardiovasc Interv. 2011. PMID: 21349455 Free article.
Transfemoral aortic valve implantation new criteria to predict vascular complications.
Hayashida K, Lefèvre T, Chevalier B, Hovasse T, Romano M, Garot P, Mylotte D, Uribe J, Farge A, Donzeau-Gouge P, Bouvier E, Cormier B, Morice MC. Hayashida K, et al. Among authors: chevalier b. JACC Cardiovasc Interv. 2011 Aug;4(8):851-8. doi: 10.1016/j.jcin.2011.03.019. JACC Cardiovasc Interv. 2011. PMID: 21851897 Free article.
Is there a need for dedicated bifurcation devices?
Lefèvre T, Chevalier B, Louvard Y. Lefèvre T, et al. Among authors: chevalier b. EuroIntervention. 2010 Dec;6 Suppl J:J123-9. doi: 10.4244/EIJV6SUPJA20. EuroIntervention. 2010. PMID: 21930476 Review. No abstract available.
468 results